OneSource Specialty Pharma Inc Stock Price Today (NSE: ONESOURCE)
Fundamental Score
OneSource Specialty Pharma Inc Share Price — Live NSE/BSE Price, Fundamentals & Analysis
OneSource Specialty Pharma Inc share price today is ₹1617.10, up +1.08% on NSE/BSE as of 17 June 2026. OneSource Specialty Pharma Inc (ONESOURCE) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹18.39K (Cr). The 52-week high for ONESOURCE share price is ₹2248.00 and the 52-week low is ₹1057.00. At a P/E ratio of 133.33x, ONESOURCE is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 3.34% and a debt-to-equity ratio of 0.22.
OneSource Specialty Pharma Inc Share Price Chart — NSE/BSE Historical Performance
OneSource Specialty Pharma Inc share price chart: -2.68% return over the past month. 52-week high ₹2248.00, 52-week low ₹1057.00.
OneSource Specialty Pharma Inc — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1820.00 | ₹1847.80 | ₹1775.00 | ₹1828.60 | 3.64L (Cr) | |
| ₹1793.00 | ₹1884.00 | ₹1791.00 | ₹1837.80 | 4.06L (Cr) | |
| ₹1791.10 | ₹1888.40 | ₹1771.60 | ₹1824.60 | 6.05L (Cr) | |
| ₹1821.90 | ₹1821.90 | ₹1760.40 | ₹1791.10 | 1.55L (Cr) | |
| ₹1800.00 | ₹1823.90 | ₹1773.00 | ₹1805.60 | 1.81L (Cr) | |
| ₹1826.00 | ₹1844.50 | ₹1780.20 | ₹1806.80 | 2.97L (Cr) | |
| ₹1861.80 | ₹1873.90 | ₹1821.00 | ₹1834.50 | 1.18L (Cr) | |
| ₹1888.00 | ₹1888.00 | ₹1842.20 | ₹1861.80 | 1.52L (Cr) | |
| ₹1848.00 | ₹1905.00 | ₹1831.50 | ₹1867.40 | 2.69L (Cr) | |
| ₹1810.00 | ₹1871.00 | ₹1810.00 | ₹1854.50 | 1.50L (Cr) |
OneSource Specialty Pharma Inc — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1793.00 | ₹1884.00 | ₹1775.00 | ₹1828.60 | +1.99% | |
| ₹1774.00 | ₹1917.80 | ₹1704.70 | ₹1824.60 | +2.85% | |
| ₹1480.70 | ₹1870.00 | ₹1316.40 | ₹1738.10 | +17.38% | |
| ₹1289.60 | ₹1542.80 | ₹1231.00 | ₹1473.30 | +14.24% | |
| ₹1200.00 | ₹1395.80 | ₹1102.00 | ₹1346.80 | +12.23% | |
| ₹1809.00 | ₹1809.00 | ₹1057.00 | ₹1194.50 | -33.97% | |
| ₹1536.00 | ₹1824.00 | ₹1515.20 | ₹1810.60 | +17.88% | |
| ₹1854.10 | ₹1925.00 | ₹1494.70 | ₹1532.20 | -17.36% | |
| ₹1823.00 | ₹1896.70 | ₹1775.00 | ₹1854.10 | +1.71% | |
| ₹1891.00 | ₹1921.90 | ₹1681.40 | ₹1840.40 | -2.68% | |
| ₹1960.00 | ₹1964.30 | ₹1792.40 | ₹1892.20 | -3.46% | |
| ₹2201.30 | ₹2231.90 | ₹1930.10 | ₹1974.00 | -10.33% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
OneSource Specialty Pharma Inc Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
OneSource Specialty Pharma Inc Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ONESOURCE across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (127.55%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.22)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Institutional Confidence (FII+DII: 37.87%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
8 factors identified
Below-Average Return on Equity (3.34%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (5.52%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 133.33x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Interest Coverage (1.87x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-1969.92 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (29.77%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
High Share Pledging Risk (26.04%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
OneSource Specialty Pharma Inc vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare OneSource Specialty Pharma Inc with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
OneSource Specialty Pharma IncOneSource Speci...Selected✓ ONESOURCE • 544292 | 5.5/100 | ₹1617.10₹1617 | ₹18392.12₹18392.12 | 133.33Average 133.3 Average | 3.34%Poor 3.34% Poor | 5.52%Poor 5.52% Poor | 0.22Excellent 0.2 Excellent | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
OneSource Specialty Pharma Inc Quarterly Performance
Latest quarterly metrics for ONESOURCE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
12.49%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
127.55%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
OneSource Specialty Pharma Inc Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ONESOURCE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
OneSource Specialty Pharma Inc Financial Statements
Annual income statement, balance sheet and cash flow for OneSource Specialty Pharma Inc (ONESOURCE) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for OneSource Specialty Pharma Inc
About ONESOURCE (OneSource Specialty Pharma Inc)
OneSource Specialty Pharma Inc. is a dynamic pharmaceutical company dedicated to innovating and improving patient lives through specialized drug development and commercialization. ...Focused on niche therapeutic areas, OneSource concentrates its efforts on creating targeted solutions for complex medical conditions where unmet needs persist. Their approach emphasizes rigorous scientific research, cutting-edge formulation technologies, and strategic partnerships to bring high-quality, effective medications to market. The company operates with a commitment to ethical practices and prioritizes patient safety and well-being in every aspect of its operations. OneSource distinguishes itself within the pharmaceutical landscape by integrating research and development with advanced manufacturing capabilities. This synergy allows for streamlined product development cycles, ensuring efficient progression from laboratory to patient. The company's state-of-the-art facilities are equipped to handle a diverse range of dosage forms and delivery systems, including both oral and injectable medications. Furthermore, OneSource actively seeks collaborations with academic institutions and other pharmaceutical companies to leverage expertise and accelerate the discovery and development of novel therapies. Driven by a team of experienced scientists, clinicians, and business professionals, OneSource is committed to expanding its product portfolio and geographic reach. The company's strategic vision involves identifying and capitalizing on emerging market opportunities, while maintaining a steadfast dedication to scientific rigor and patient-centric values. As OneSource continues to grow, it remains dedicated to making a meaningful impact on global healthcare by providing innovative, specialized pharmaceuticals that improve patient outcomes and enhance the quality of life.
Company Details
Key Leadership
ONESOURCE Share Price: Frequently Asked Questions
What is the current share price of OneSource Specialty Pharma Inc?
OneSource Specialty Pharma Inc (ONESOURCE) trades at ₹1617.10 on NSE and BSE. Market cap ₹18.39K (Cr). Educational data only.
What is the P/E ratio of OneSource Specialty Pharma Inc?
OneSource Specialty Pharma Inc has a P/E of 133.33x vs industry average 31.77x.
What is the Bull Run score for OneSource Specialty Pharma Inc?
OneSource Specialty Pharma Inc has a Bull Run score of 5.5/100 based on 25+ financial parameters.
Does OneSource Specialty Pharma Inc pay dividends?
OneSource Specialty Pharma Inc has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of OneSource Specialty Pharma Inc?
OneSource Specialty Pharma Inc has ROE of 3.34%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of OneSource Specialty Pharma Inc?
OneSource Specialty Pharma Inc has debt-to-equity of 0.22.
Is OneSource Specialty Pharma Inc a good investment?
Bull Run gives OneSource Specialty Pharma Inc a score of 5.5/100. This is not investment advice — consult a SEBI-registered advisor.